Pharming Group N.V.

OTCPK:PHGUF

Pays-Bas / Santé / Biotechnologie

Aperçu

Actualités

Historique des finances 5 ans

Prix Action

0,90 USD


Key Metrics	Latest
Total Revenue	297,2 M
Adjusted EBITDA	7,449 M
EBITDA Margin	2,5%
Net Profit Margin	-3,7%
Total Assets	400,8 M
Total Debt	112,3 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	212.17	198.87	205.62	245.32	297.20	297.20	245.32	297.20
% Growth		(0.06)	0.03	0.19	0.21			0.21

Adjusted EBITDA	82.54	30.39	15.89	(15.29)	7.45	7.45	(15.29)	7.45
% Margin	0.39	0.15	0.08	(0.06)	0.03	0.03	(0.06)	0.03

Adjusted EBIT	76.26	24.00	10.37	(21.75)	(8.62)	(8.62)	(21.75)	(8.62)
% Margin	0.36	0.12	0.05	(0.09)	(0.03)	(0.03)	(0.09)	(0.03)

Adjusted Net Income	43.66	23.64	8.73	(21.97)	(11.03)	(11.03)	(21.97)	(11.03)
% Margin	0.21	0.12	0.04	(0.09)	(0.04)	(0.04)	(0.09)	(0.04)

Adjusted Basic EPS	0.07	0.04	0.01	(0.03)	(0.02)	(0.02)	(0.03)	(0.02)

Calculs d'appui

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Press Release
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	212	199	206	245	297	297	245	297
% Growth	NA	-6.3%	3.4%	19.3%	21.1%			21.1%

Cost of Revenue	(24)	(21)	(18)	(25)	(35)	(35)	(25)	(35)
Gross Profit	189	178	188	220	262	262	220	262
% Revenue	88.9%	89.4%	91.5%	89.7%	88.1%	88.1%	89.7%	88.1%

Research and Development	(39)	(70)	(53)	(69)	(83)	(83)	(69)	(83)
Selling and Marketing	(52)	(59)	(86)	(124)	(119)	(119)	(124)	(119)
General and Admin	(24)	(32)	(42)	(51)	(71)	(71)	(51)	(71)
Other Inc / (Exp)	(25)	13	12	14	5	5	14	5
Total Operating Exp	(139)	(149)	(168)	(230)	(267)	(267)	(230)	(267)

Operating Income	49	29	20	(10)	(5)	(5)	(10)	(5)
% Revenue	23.2%	14.6%	9.9%	-4.0%	-1.8%	-1.8%	-4.0%	-1.8%

Interest Expense	(5)	(6)	(5)	(2)	(3)	(3)	(2)	(3)
Pre-tax Income	44	23	15	(12)	(9)	(9)	(12)	(9)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(6)	(7)	(1)	1	(3)	(3)	1	(3)
Net Income to Company	38	16	14	(11)	(11)	(11)	(11)	(11)
% Margin	17.8%	8.0%	6.7%	-4.3%	-3.7%	-3.7%	-4.3%	-3.7%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	38	16	14	(11)	(11)	(11)	(11)	(11)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	38	16	14	(11)	(11)	(11)	(11)	(11)
% Margin	17.8%	8.0%	6.7%	-4.3%	-3.7%	-3.7%	-4.3%	-3.7%

As Reported
Basic EPS (Continuing Ops)	0.06	0.02	0.02	(0.02)	(0.02)	(0.02)	(0.02)	(0.02)
Diluted EPS (Continuing Ops)	0.05	0.02	0.02	(0.02)	(0.02)	(0.02)	(0.02)	(0.02)

WA Basic Shares Out.	636.27	642.01	648.68	657.02	689.19	689.19	657.02	689.19
WA Diluted Shares Out.	682.74	701.15	707.14	657.02	689.19	689.19	657.02	689.19

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	44	23	15	(12)	(9)	(9)	(12)	(9)
Addback: Net Interest Expense	5	6	5	2	3	3	2	3
Addback: Other Non Operating Expenses, Total	19	(15)	(3)	3	(3)	(3)	3	(3)
Addback: Depreciation & Amortization	6	6	6	6	16	16	6	16
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	(0)	(0)	(11)	1	0	0	1	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	(21)	0	0	(21)	0
Addback: Asset Writedown	0	10	4	5	0	0	5	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	8	0	0	0	0	0	0	0
Adjusted EBITDA	83	30	16	(15)	7	7	(15)	7
% Margin	38.9%	15.3%	7.7%	-6.2%	2.5%	2.5%	-6.2%	2.5%

Adjusted EBIT	76	24	10	(22)	(9)	(9)	(22)	(9)
% Margin	35.9%	12.1%	5.0%	-8.9%	-2.9%	-2.9%	-8.9%	-2.9%

Adjusted Net Income Reconciliation
Net Income to Company	38	16	14	(11)	(11)	(11)	(11)	(11)
Addback: Unusual Items	8	10	(7)	(15)	0	0	(15)	0
Less: Tax Benefit of Unusual Items (26%)	(2)	(3)	2	4	0	0	4	0
Adjusted Net Income	44	24	9	(22)	(11)	(11)	(22)	(11)
% Margin	20.6%	11.9%	4.2%	-9.0%	-3.7%	-3.7%	-9.0%	-3.7%

Erreur de Chargement

Pharming Group N.V.

OTCPK:PHGUF

Pays-Bas / Santé / Biotechnologie

Historique des finances 5 ans